November 16, 2016 - By Louis Casey · 0 Comments
The stock of Sophiris Bio Incorporated (NASDAQ:SPHS) registered an increase of 35.9% in short interest. SPHS’s total short interest was 1.93M shares in November as published by FINRA. Its up 35.9% from 1.42 million shares, reported previously. With 1.93M shares average volume, it will take short sellers 1 days to cover their SPHS’s short positions. The short interest to Sophiris Bio Incorporated’s float is 11.13%. About 433,367 shares traded hands. Sophiris Bio Inc (NASDAQ:SPHS) has risen 106.62% since April 14, 2016 and is uptrending. It has outperformed by 101.93% the S&P500.
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada biopharmaceutical firm focused on the research, development and commercialization of products for the treatment of urological diseases. The company has a market cap of $84.60 million. The Firm has activities based in San Diego developing a treatment for benign prostatic hyperplasia or enlarged prostate). It currently has negative earnings. The Firm has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan.
Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 1.98, from 2.75 in 2016Q1. The ratio dropped, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Wells Fargo And Co Mn has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Fincl Bank Of Montreal Can holds 0% or 1,632 shares in its portfolio. Morgan Stanley, a New York-based fund reported 225 shares. Airain accumulated 32,017 shares or 0% of the stock. Kcg Holdg Inc accumulated 0% or 17,013 shares. Moreover, Savings Bank Of Mellon has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 18,866 shares. Citadel Advsr Ltd Liability Corp last reported 49,176 shares in the company. Creative Planning last reported 900 shares in the company. Palo Alto Limited Liability Co, a California-based fund reported 494,000 shares. Royal Comml Bank Of Canada holds 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 5,971 shares. Jane Street Group Limited Liability Co owns 27,176 shares or 0% of their US portfolio. Vanguard Group accumulated 331,000 shares or 0% of the stock. Ladenburg Thalmann Svcs last reported 0% of its portfolio in the stock. Rock Springs Ltd Partnership holds 0.08% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 490,000 shares. Deutsche Financial Bank Ag holds 0% or 20,822 shares in its portfolio.
Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. The stock of Sophiris Bio Inc (NASDAQ:SPHS) earned “Overweight” rating by Piper Jaffray on Tuesday, August 30. The rating was initiated by TH Capital with “Buy” on Thursday, September 15. The stock of Sophiris Bio Inc (NASDAQ:SPHS) has “Buy” rating given on Thursday, September 15 by Roth Capital.
Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.
More important recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: Prnewswire.com which released: “Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business …” on November 09, 2016, also Prnewswire.com published article titled: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering”, Prnewswire.com published: “Sophiris Bio Prices Public Offering of Common Shares and Warrants” on August 23, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) was released by: Prnewswire.com and their article: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” with publication date: May 05, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey